LDC and JT team up for the discovery of new therapies

12-Oct-2023 - The Lead Discovery Center GmbH (LDC) and Japan Tobacco Inc. (JT) have closed a collaboration agreement to discover new first-in-class therapeutic approaches, focusing around novel chemical entities for the treatment of various diseases with significant unmet medical need. Over a period of up to ...

Start-up CalTIC secures up to EUR 3 million in seed financing to develop a new class of drugs targeting TRPC channels

Promising new approach for the treatment of widespread conditions, including metabolic diseases, obesity, and heart hypertrophy

29-Sep-2022 - The KHAN Technology Transfer Fund I (KHAN-I) has committed up to EUR 3 million in milestone-dependent payments to CalTIC, a Dortmund based start-up, for the discovery of a new class of drugs. The start-up builds on a long-term collaboration between the Lead Discovery Center GmbH (LDC), the Max ...

LDC and Cumulus Oncology Announce Collaboration

Discovery and development of novel oncology therapies

23-Mar-2021 - The Lead Discovery Center GmbH (LDC) and Cumulus Oncology announce the signing of a collaboration agreement enabling the two organisations to accelerate the discovery and development of novel oncology therapies. The collaboration builds on the complementary expertise of both organisations. LDC ...

New medicines against severe inflammatory diseases

Start-up Quench Bio closes USD 50M Series A financing

28-Feb-2020 - The Lead Discovery Center GmbH (LDC), the Max Planck Society (MPG) and Max Planck Innovation (MI) announce that their associated company Quench Bio Inc., Cambridge, USA has raised USD 50 million in a Series A financing round. The financing was led by RA Capital Management (RA Capital) and ...

Investment Plan for Europe: Successful launch of Tech Transfer Fund “KHAN-I”

13-Sep-2019 - Khanu Management GmbH (Khanu), a drug discovery focused fund management team, announces the successful launch of KHAN Technology Transfer Fund I GmbH & Co KG (KHAN-I), based in Dortmund, Germany. The European Investment Fund (EIF, Luxemburg), the Austria Wirtschaftsservice GmbH (Vienna, Austria) ...

LDC opens branch in Munich

Focus on discovery of therapeutic antibodies

24-Apr-2018 - The Lead Discovery Center GmbH (LDC) has established a branch - LDC Biologics - in the Munich Biocluster. While the team in Dortmund focuses on chemical compounds (small molecules), in Munich the emphasis will be on the development of therapeutic antibodies. LDC Biologics will produce, optimise ...

Max Planck Society grants technology for cancer therapy

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center announce cancer research collaboration

18-Jul-2017 - Daiichi Sankyo, Max Planck Innovation, and the Lead Discovery Center have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center. This new ...

LDC and SOTIO Enter License and Collaboration Agreement for First-in-class Cancer Metabolism Program

18-Apr-2017 - The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism. It was discovered at the Max Planck Institute for ...

LDC and Roche will jointly advance innovative drug discovery projects

LDC Enters new Industry Partnership for the Discovery of Novel Medicines

25-Jan-2016 - The Lead Discovery Center GmbH (LDC) and Roche will collaborate to identify and leverage innovative therapeutic opportunities that address diseases of unmet medical need across several disease areas. Projects will be sourced from the LDC’s academic partners, as well as from Roche’s innovation ...

LDC to Collaborate with Johnson & Johnson Innovation on Acceleration of Academic Drug Discovery Initiatives

16-Jun-2015 - The Lead Discovery Center GmbH (LDC) and Johnson & Johnson Innovation Ltd., will collaborate to identify and accelerate drug candidates for the treatment and prevention of diseases with high unmet medical needs.Over a two-year period, LDC and the team from the Johnson & Johnson’s London ...